Photodynamic therapy using an anti-EGF receptor antibody complexed with verteporfin nanoparticles: A proof of concept study

Noriaki Kameyama, Sachiko Matsuda, Osamu Itano, Arisa Ito, Tomohiro Konno, Tsunenori Arai, Kazuhiko Ishihara, Masakazu Ueda, Yuukou Kitagawa

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Photodynamic therapy (PDT) is a noninvasive optical treatment method in which the topical or systemic delivery of photosensitizing drugs is followed by irradiation with broadband red light. Coupling photosensitizers with a specific antibody may allow this approach to target specific cancers. This study determines the antitumor efficacy of coupling verteporfin (Visudyne ®), a hydrophobic polyporphryin oligomer, with an antiepidermal growth factor receptor (anti-EGFR) antibody. Poly[2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate-co-p-nitrophenylcarbonyloxyethyl methacrylate] (PMBN) was conjugated with an anti-EGFR antibody and mixed with verteporfin (verteporfin-PMBN-antibody complex). Tumor-bearing mice were intravenously injected with the verteporfin-PMBN-antibody complex or verteporfin plus PMBN without the antibody. Irradiation was conducted at 640 nm with a dose of 75 J/cm 2. The fluorescence intensity in A431 cells in vitro was threefold higher after exposure to verteporfin-PMBN-antibody complex than after exposure to verteporfin-PMBN. In A431 tumor-bearing mice, the intratumor concentration of verteporfin was 9.4 times higher than that of the skin, following administration of the verteporfin-PMBN-antibody complex. Tumor size significantly decreased within 8 days in mice treated with verteporfin-PMBN- antibody complex compared with those treated with verteporfin-PMBN. PDT using a PMBN-verteporfin-antibody complex offers a promising anticancer therapy.

Original languageEnglish
Pages (from-to)697-704
Number of pages8
JournalCancer Biotherapy and Radiopharmaceuticals
Volume26
Issue number6
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

Photochemotherapy
Epidermal Growth Factor Receptor
Nanoparticles
Antibodies
Growth Factor Receptors
verteporfin
Neoplasms
polymyxin B nonapeptide
Photosensitizing Agents
Methacrylates
Fluorescence

Keywords

  • antibody complex
  • cancer
  • endothelial growth factor receptor
  • photodynamic therapy
  • verteporfin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology

Cite this

Photodynamic therapy using an anti-EGF receptor antibody complexed with verteporfin nanoparticles : A proof of concept study. / Kameyama, Noriaki; Matsuda, Sachiko; Itano, Osamu; Ito, Arisa; Konno, Tomohiro; Arai, Tsunenori; Ishihara, Kazuhiko; Ueda, Masakazu; Kitagawa, Yuukou.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 26, No. 6, 01.12.2011, p. 697-704.

Research output: Contribution to journalArticle

Kameyama, Noriaki ; Matsuda, Sachiko ; Itano, Osamu ; Ito, Arisa ; Konno, Tomohiro ; Arai, Tsunenori ; Ishihara, Kazuhiko ; Ueda, Masakazu ; Kitagawa, Yuukou. / Photodynamic therapy using an anti-EGF receptor antibody complexed with verteporfin nanoparticles : A proof of concept study. In: Cancer Biotherapy and Radiopharmaceuticals. 2011 ; Vol. 26, No. 6. pp. 697-704.
@article{aabab861717d41b89a9497f2a813c947,
title = "Photodynamic therapy using an anti-EGF receptor antibody complexed with verteporfin nanoparticles: A proof of concept study",
abstract = "Photodynamic therapy (PDT) is a noninvasive optical treatment method in which the topical or systemic delivery of photosensitizing drugs is followed by irradiation with broadband red light. Coupling photosensitizers with a specific antibody may allow this approach to target specific cancers. This study determines the antitumor efficacy of coupling verteporfin (Visudyne {\circledR}), a hydrophobic polyporphryin oligomer, with an antiepidermal growth factor receptor (anti-EGFR) antibody. Poly[2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate-co-p-nitrophenylcarbonyloxyethyl methacrylate] (PMBN) was conjugated with an anti-EGFR antibody and mixed with verteporfin (verteporfin-PMBN-antibody complex). Tumor-bearing mice were intravenously injected with the verteporfin-PMBN-antibody complex or verteporfin plus PMBN without the antibody. Irradiation was conducted at 640 nm with a dose of 75 J/cm 2. The fluorescence intensity in A431 cells in vitro was threefold higher after exposure to verteporfin-PMBN-antibody complex than after exposure to verteporfin-PMBN. In A431 tumor-bearing mice, the intratumor concentration of verteporfin was 9.4 times higher than that of the skin, following administration of the verteporfin-PMBN-antibody complex. Tumor size significantly decreased within 8 days in mice treated with verteporfin-PMBN- antibody complex compared with those treated with verteporfin-PMBN. PDT using a PMBN-verteporfin-antibody complex offers a promising anticancer therapy.",
keywords = "antibody complex, cancer, endothelial growth factor receptor, photodynamic therapy, verteporfin",
author = "Noriaki Kameyama and Sachiko Matsuda and Osamu Itano and Arisa Ito and Tomohiro Konno and Tsunenori Arai and Kazuhiko Ishihara and Masakazu Ueda and Yuukou Kitagawa",
year = "2011",
month = "12",
day = "1",
doi = "10.1089/cbr.2011.1027",
language = "English",
volume = "26",
pages = "697--704",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Photodynamic therapy using an anti-EGF receptor antibody complexed with verteporfin nanoparticles

T2 - A proof of concept study

AU - Kameyama, Noriaki

AU - Matsuda, Sachiko

AU - Itano, Osamu

AU - Ito, Arisa

AU - Konno, Tomohiro

AU - Arai, Tsunenori

AU - Ishihara, Kazuhiko

AU - Ueda, Masakazu

AU - Kitagawa, Yuukou

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Photodynamic therapy (PDT) is a noninvasive optical treatment method in which the topical or systemic delivery of photosensitizing drugs is followed by irradiation with broadband red light. Coupling photosensitizers with a specific antibody may allow this approach to target specific cancers. This study determines the antitumor efficacy of coupling verteporfin (Visudyne ®), a hydrophobic polyporphryin oligomer, with an antiepidermal growth factor receptor (anti-EGFR) antibody. Poly[2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate-co-p-nitrophenylcarbonyloxyethyl methacrylate] (PMBN) was conjugated with an anti-EGFR antibody and mixed with verteporfin (verteporfin-PMBN-antibody complex). Tumor-bearing mice were intravenously injected with the verteporfin-PMBN-antibody complex or verteporfin plus PMBN without the antibody. Irradiation was conducted at 640 nm with a dose of 75 J/cm 2. The fluorescence intensity in A431 cells in vitro was threefold higher after exposure to verteporfin-PMBN-antibody complex than after exposure to verteporfin-PMBN. In A431 tumor-bearing mice, the intratumor concentration of verteporfin was 9.4 times higher than that of the skin, following administration of the verteporfin-PMBN-antibody complex. Tumor size significantly decreased within 8 days in mice treated with verteporfin-PMBN- antibody complex compared with those treated with verteporfin-PMBN. PDT using a PMBN-verteporfin-antibody complex offers a promising anticancer therapy.

AB - Photodynamic therapy (PDT) is a noninvasive optical treatment method in which the topical or systemic delivery of photosensitizing drugs is followed by irradiation with broadband red light. Coupling photosensitizers with a specific antibody may allow this approach to target specific cancers. This study determines the antitumor efficacy of coupling verteporfin (Visudyne ®), a hydrophobic polyporphryin oligomer, with an antiepidermal growth factor receptor (anti-EGFR) antibody. Poly[2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate-co-p-nitrophenylcarbonyloxyethyl methacrylate] (PMBN) was conjugated with an anti-EGFR antibody and mixed with verteporfin (verteporfin-PMBN-antibody complex). Tumor-bearing mice were intravenously injected with the verteporfin-PMBN-antibody complex or verteporfin plus PMBN without the antibody. Irradiation was conducted at 640 nm with a dose of 75 J/cm 2. The fluorescence intensity in A431 cells in vitro was threefold higher after exposure to verteporfin-PMBN-antibody complex than after exposure to verteporfin-PMBN. In A431 tumor-bearing mice, the intratumor concentration of verteporfin was 9.4 times higher than that of the skin, following administration of the verteporfin-PMBN-antibody complex. Tumor size significantly decreased within 8 days in mice treated with verteporfin-PMBN- antibody complex compared with those treated with verteporfin-PMBN. PDT using a PMBN-verteporfin-antibody complex offers a promising anticancer therapy.

KW - antibody complex

KW - cancer

KW - endothelial growth factor receptor

KW - photodynamic therapy

KW - verteporfin

UR - http://www.scopus.com/inward/record.url?scp=83455262972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83455262972&partnerID=8YFLogxK

U2 - 10.1089/cbr.2011.1027

DO - 10.1089/cbr.2011.1027

M3 - Article

C2 - 21861705

AN - SCOPUS:83455262972

VL - 26

SP - 697

EP - 704

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 6

ER -